Bexorg has secured $23 million in a Series A financing round led by Engine Ventures, bringing its total funding to $42.5 million, according to the company. The round also included participation from Connecticut Innovations, E1 Ventures, Amplify Partners, and Starbloom Capital.
The proceeds will be used to expand and optimize Bexorg’s AI engine, which the company claims is trained on clinically predictive data from whole human brains. The company said that it will also advance its internal central nervous system (CNS) drug discovery programs and in-licensed assets through new strategic partnerships.
Bexorg presents its platform as an alternative to traditional cellular and animal models, which it argues fail to adequately reflect human biology—and are a factor in CNS clinical trial failure rates exceeding 95%. The company claims its integrated platform uses experimental data from diseased and non-diseased donated whole human brains to feed AI models that generate high-fidelity targets, novel biomarkers, and decision criteria for drug development.
Since its founding in 2021 by Zvonimir Vrselja and Nenad Sestan at Yale University, Bexorg has expanded its proprietary data set to include hundreds of whole-brain experiments across Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. The company also reported collaborations with the University of Oxford, the UK Medical Research Council, and Biohaven Ltd.
In conjunction with the financing, Ann DeWitt of Engine Ventures and David Beyer of Amplify Partners will join Bexorg’s board of directors.
